Lack of HER-2/neu overexpression in non-Hodgkin's lymphoma

Anticancer Research

Volumn 24, Issue 5 B, 2004, Pages 3233-3237

  Lüftner, Diana ^a   Genvresse, Isabelle ^a   Geppert, Rita ^a   Kaufmann, Olaf ^a   Dietel, Manfred ^a   Possinger, Kurt ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Diffuse large cell lymphoma; HER 2 neu; Non Hodgkin's lymphoma

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; MONOCLONAL ANTIBODY; TRASTUZUMAB;

ADULT; AGED; ARTICLE; BLOOD ANALYSIS; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE OVEREXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; LARGE CELL LYMPHOMA; LYMPH NODE; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; ONCOGENE NEU; PRIORITY JOURNAL; STAINING;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; LYMPH NODES; LYMPHOMA, NON-HODGKIN; LYMPHOMA, T-CELL; MALE; MIDDLE AGED; PARAFFIN EMBEDDING; RECEPTOR, ERBB-2;

EID: 6344229551     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Padhy LC, Shih C, Cowing D, Finkelstein R and Weinberg RA: Identification of a phosphoprotein specifically induced by the transforming DNA of rat neuroblastomas. Cell 28: 865-871, 1982.
2. Bargmann CI, Hung MC and Weinberg RA: The neu oncogene encodes an epidermal growth factor receptor-related protein. Nature 319: 226-230, 1986.
3. Brandt-Rauf PW, Pincus MR and Carney WP: The c-erbB-2 protein in oncogenesis: molecular structure to molecular epidemiology. Crit Rev Oncog 5(2-3): 313-329, 1994.
4. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A and McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235: 177-182, 1987.
5. Slamon DJ, Godolphin W, Jones LA et al: Studies of the Her-2/neu proto-oncogene in human and ovarian cancer. Science 244: 707-712, 1989.
6. Kern JA, Schwartz DA, Nordberg JE et al: P185HER2 expression in human lung adenocarcinoma predicts shortened survival. Cancer Res 50: 184-187, 1990.
7. Press MF, Pike MC, Hung G et al: Amplification and overexpression of HER-2/neu in carcinomas of the salivary gland: correlation with poor prognosis. Cancer Res 54: 5675-5682, 1994.
8. Ross JS and Fletcher JA: The HER-2/neu oncogene: prognostic factor, predictive factor and target therapy. Cancer Biol 9: 125-138, 1999.
9. Hanna W: Testing for HER2 status. Oncology 62(suppl 2): 22-30, 2001.
10. Codony-Servat J, Albanell J, Lopez-Talavera JC, Arribas J and Baselga J: Cleavage of the HER2 ectodomain is a pervanadate-activable process that is inhibited by the tissue inhibitor of metalloproteases-1 in breast cancer cells. Cancer Res 59(6): 1196-201, 1999.
11. Harris L, Lüftner D, Jäger W and Robertson JF: C-erbB-2 in serum of patients with breast cancer. Int J Biol Markers 14: 8-15, 1999.
12. Cobleigh MA, Vogel CL, Tripathy D et al: Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17: 2639-2648, 1999.
13. Imamura N, Miyazawa T, Mtasiwa D and Kuramoto A: Co-expression of N-ras p21 and C-erbB-2 (neu) oncogene products by common ALL antigen-positive aggressive diffuse lymphoma. Lancet 336: 825-826, 1990.
14. Mineshita M, Miyazawa T, Doi M, Kurata T, Furukawa N and Imamura N: Aggressive diffuse lymphoma with malignant pleural effusion expressing c-erbB-2 (neu) oncogene products. Nihon Kyobu Shikkan Gakkai Zasshi 31: 744-748, 1993.
15. Cheung TH, Wong YF, Chung TKH, Maimonis P and Chang AMZ: Clinical use of serum c-erbB-2 in patients with ovarian masses. Gynecol Obstet Invest 48: 133-137, 1999.
16. Smolewski P, Niewiadomska H, Blonski JZ, Robak T and Krykowski E: Expression of proliferating cell nuclear antigen (PCNA) and p53, bcl-2 or C-erb B-2 proteins on Reed-Sternberg cells: prognostic significance in Hodgkin's disease. Neoplasma 45: 140-147, 1998.
17. Cook GB, Neaman IE, Goldblatt JL et al: Clinical utility of serum HER-2/neu testing on the Bayer Immuno 1 automated system in breast cancer. Anticancer Res 21: 1465-1470, 2001.
18. Jacobs TW, Gown AM, Yaziji H, Barnes MJ and Schnitt SJ: Specificity of HepcepTest in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system. J Clin Oncol 17: 1983-1987, 1999.
19. Bairey O, Pazgal I, Okon E, Shaklai M and Morgenshtern S: Lack of HER-2/neu expression in Hodgkin and non-Hodgkin lymphoma. Arch.Pathol.Lab Med 126: 574-576, 2002.
20. Nelson NJ: Experts debite value of Her-2 testing methods. J Natl Cancer Inst 92: 292-294, 2000.
21. Press MF, Hung G, Godolphin W and Slamon DJ: Sensitivity of HER-2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression. Cancer Res 54: 2771-2777, 1994.
22. Kay EW, Walsh CJ, Cassidy M, Curran B and Leader M: C-erbB-2 immunostaining: problems with interpretation. J Clin Pathol 47: 816-822, 1994.
23. Farabegoli F, Ceccarelli C, Santini D et al: C-erbB-2 overexpression in amplified and non-amplified breast carcinoma samples. Int J Cancer 84: 273-277, 1999.
24. Jacobs TW, Prioleau JE, Stillman IE and Schnitt SJ: Loss of tumor marker-immunostaining intensity on stored paraffin slides of breast cancer. J Natl Cancer Inst 88: 1054-1059, 1996.